>Core business momentum remains soft on overprovision reversals - Sales increased 22% y-o-y in Q3 2024 (vs -7% in Q2, +12% in Q1 and -20% in Q4). Biopharma sales decreased 5% y-o-y in Q3 2024 (compared to -18% in Q2, +25% in Q1 and -32% in Q4) namely owing to a reversal of overprovisions for deductions applicable under the French compassionate use programme, excluding this effect, 9M 2024 Lurbi sales in Europe are growing at a +14% pace (vs +16% in H1). Royalties post...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.